Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report

Abstract Background Nucleoside analogues (NAs) such as entecavir are required for at least 12 months when patients with resolved hepatitis B virus (HBV) infection develop HBV reactivation. Entecavir treatment does not always achieve hepatitis B surface antigen (HBsAg) seroconversion. The cessation o...

Full description

Bibliographic Details
Main Authors:	Maki Ohkubo, Kuniaki Fukuda, Shigeru Chiba, Masato Homma
Format:	Article
Language:	English
Published:	BMC 2023-12-01
Series:	Journal of Pharmaceutical Health Care and Sciences
Subjects:	HBsAg seroconversion HBcrAg levels HBV reactivation HBV rebound
Online Access:	https://doi.org/10.1186/s40780-023-00321-x

Similar Items

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
by: Jing Zhao, et al.
Published: (2023-03-01)

Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B
by: Zhan-Qing Zhang, et al.
Published: (2017-12-01)

Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report
by: Gian Paolo Caviglia, et al.
Published: (2021-11-01)

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study
by: Milan J. Sonneveld, et al.
Published: (2023-08-01)

Prediction for HBsAg seroconversion in children with chronic hepatitis B
by: Yan-Wei Zhong, et al.
Published: (2021-12-01)

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment
by: Lisa Sandmann, et al.
Published: (2024-02-01)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
by: Lorenzo Piermatteo, et al.
Published: (2023-12-01)

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis
by: Gian Paolo Caviglia, et al.
Published: (2021-01-01)

Spontaneous HBsAg seroconversion after severe flare of chronic hepatitis B infection
by: Akif Altinbaş, M.D., et al.
Published: (2010-04-01)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
by: Romina Salpini, et al.
Published: (2020-01-01)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
by: Hui Ma, et al.
Published: (2016-01-01)

Drug Discovery Study Aimed at a Functional Cure for HBV
by: Takehisa Watanabe, et al.
Published: (2022-06-01)

Investigation of HBV DNA in HBsAg positive patients
by: Nihal Secil Bati, et al.
Published: (2017-12-01)

Analysis of S gene characteristic sequences and changes in properties of protein expression in HBV ASCs with low-level HBsAg
by: Yu Yu, et al.
Published: (2022-09-01)

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients
by: Wen-Xin Wang, et al.
Published: (2022-07-01)

Characteristics of HBcrAg in HBsAg-/HBV DNA+ blood donors in Wuxi area
by: Yan WANG, et al.
Published: (2024-01-01)

New perspectives of biomarkers for the management of chronic hepatitis B
by: Chih-Lin Lin, et al.
Published: (2016-12-01)

Detection of S-HBsAg Mutations in Patients with Hematologic Malignancies
by: Maria V. Konopleva, et al.
Published: (2021-05-01)

The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
by: Shengxia Yin, et al.
Published: (2023-12-01)

HIGH PREVALENCE OF HBsAg CARRIERS IN A SPECIFIC COMMUNITY IN BULGARIA
by: Zahariy Krastev, et al.
Published: (2011-10-01)

Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients
by: Xian-ding Wang, et al.
Published: (2021-01-01)

Performance of rapid test in detection of HBsAg in frozen sera
by: Firat Zafer Mengeloglu, et al.
Published: (2014-03-01)

ADCC-Mediated CD56dim NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection
by: Wen-Han Yu, et al.
Published: (2018-02-01)

Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain
by: Lanlan Liu, et al.
Published: (2024-07-01)

Is Quantitative HBsAg Measurement a Reliable Substitute for HBV DNA Quantitation?
by: Mohammad Reza Mahdavi, et al.
Published: (2015-07-01)

HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative
by: Tai-Chung Tseng, et al.
Published: (2024-01-01)

HBsAg in Cord Blood Qf Newborns of HBsAg-Positive Mothers
by: Adnan S. Wiharta, et al.
Published: (2018-11-01)

Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B
by: Yong-Hong Wang, et al.
Published: (2024-03-01)

Correlation between quantitative HBsAg and quantitative HBV DNA in chronic hepatitis B patients: a systematic review and meta-analysis
by: Ummi Maimunah, et al.
Published: (2024-05-01)

Geographic distribution of HBsAg subtypes in Brazil Distribuição geográfica dos subtipos de antígenos de HBsAg no Brasil
by: Ana Maria Coimbra Gaspar, et al.
Published: (1987-06-01)

Early Dynamics of Hepatitis B Virus (HBV)-DNA and Surface Antigen (HBsAg) in Ramp-Up Phase of Viremia: Implications for Performance Evaluation of Blood Screening Assays
by: Harry van Drimmelen, et al.
Published: (2022-08-01)

Detection and prevalence of HBsAg and HBV DNA among visiting patients attending health facilities in Nigeria
by: Uchenna D. Abazuh, et al.
Published: (2023-07-01)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers
by: Luisa Roade, et al.
Published: (2023-10-01)

The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy
by: Yingfu Zeng, et al.
Published: (2024-03-01)

An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients
by: Minghui Li, et al.
Published: (2022-08-01)

New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts
by: Valentina Svicher, et al.
Published: (2019-08-01)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
by: Jaehyeon Lee, et al.
Published: (2023-02-01)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
by: Ying Yan, et al.
Published: (2022-11-01)

Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection?
by: Akif Altinbas, et al.
Published: (2012-05-01)

The Prevalence of Hepatitis B Virus Surface Antigen (HBsAg) Variations and Correlation with the Clinical and Serologic Pictures in Chronic Carriers from Khorasan Province, North-East of Iran
by: Alireza Namazi, et al.
Published: (2012-04-01)